𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Plasminogen activator inhibitor type 2 (PAI-2) is present in normal human conjunctiva

✍ Scribed by M. Massaro-Giordano; C.M. Marshall; R.M. Lavker; P.J. Jensen; B.C. Risse Marsh


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
285 KB
Volume
205
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis


The purpose was to characterize plasminogen activator inhibitor type 2 (PAI-2) expression in normal human conjunctiva in vivo and in vitro. PAI-2 antigen was assayed by immunostaining and immunoblotting of extracts from normal human conjunctival epithelial lysates and conditioned media (CM) of cultured human conjunctival keratinocytes. Immunostaining of normal human conjunctival epithelia revealed that PAI-2 was found consistently in the superficial keratinocytes and, in some biopsies, also in the lower keratinocyte layers. In all cases, PAI-2 was concentrated around the cell periphery. In extracts of conjunctival epithelia and cultured conjunctival keratinocytes, PAI-2 had an apparent molecular weight of 45 kDa, consistent with the non-glycosylated form. The majority of PAI-2, approximately 90%, was cell associated, however, a small percentage of PAI-2 was released into the CM in a linear manner with time. PAI-2 in the conditioned medium had a higher molecular weight, consistent with a glycosylated form. Conjunctival PAI-2 was active, as shown by its ability to complex with a target enzyme, urokinase plasminogen activator (uPA). Although PAI-2 was detectable both in monolayer (i.e., relatively undifferentiated) conjunctival keratinocyte cultures as well as in stratified (i.e., more differentiated) cultures, steady state levels of PAI-2 were greater in the latter. PAI-2 is constitutively expressed by normal human conjunctival epithelial cells. The expression of PAI-2 throughout all epithelial layers in some biopsies of conjunctiva in vivo contrasts with the previously established distribution of PAI-2 in corneal epithelia, where it is present exclusively in the most superficial (i.e. most highly differentiated) cells. The role of PAI-2 in either tissue is unclear. However, we speculate that its distinct distribution in conjunctival versus corneal epithelia underscores inherent differences between these tissues, and may reflect specific functions of this proteinase inhibitor in both conjunctival and corneal epithelial cells.


πŸ“œ SIMILAR VOLUMES


Evidence for intracellular cleavage of p
✍ Barbara C. Risse; Nancy M. Chung; Mark S. Baker; Pamela J. Jensen πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 500 KB

Plasminogen activator inhibitor type 2 (PAI-2) is a serine proteinase inhibitor (serpin), present in high quantities in stratified squamous epithelia. Detergent extracts of human epidermis or cultured keratinocytes contain primarily active, nonglycosylated PAI-2. In keratinocytes, the vast majority

n-Butyrate induces plasminogen activator
✍ T J Smith; J J Piscatelli; V Andersen; H Wang; P Lance πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 398 KB

n-Butyrate, a short-chain aliphatic carboxylic acid n-Butyrate, a four-carbon short-chain aliphatic carwith pleiotropic actions, is present at high concentraboxylic acid, and compounds structurally related to it tions in the portal circulation and thus may play an imexert numerous actions on cells i

High tumor tissue concentration of plasm
✍ Johanna Nordengren; Margareta Fredstorp Lidebring; PΓ€r-Ola Bendahl; Nils BrΓΌnner πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 106 KB πŸ‘ 1 views

## Abstract Previous studies including various tumor types have shown different associations between tumor tissue levels of plasminogen activator inhibitor 2 (PAI‐2) and patient survival. High tumor tissue concentrations of PAI‐2 have been associated with good prognosis in patients with breast canc

Tissue inhibitor of metalloproteinase-2
✍ Muhammad Zafarullah; Suming Su; Johanne Martel-Pelletier; John A. DiBattista; Be πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 672 KB

Tissue inhibitors of metalloproteinases (TIMPs) inhibit the extracellular matrix (ECM) metalloproteinases (MMPs). To determine the source of TlMPs in synovial fluids of patients with osteoarthritis (OA), the ability of chondrocytes to express TIMP-2 and its regulation by agents found in inflammed jo